Jerusalem, Israel, September 8, 2026
Scinai Immunotherapeutics has announced a strategic refocusing of its research and development portfolio following the conclusion of its PC111 option and license arrangements with PinCell S.r.l. The company will no longer take on additional funding commitments for the preclinical PC111 program and will instead concentrate capital and management resources on its NanoAb antibody platform and the growing commercial activities of Scinai Biopharma Services, its contract development and manufacturing organization (CDMO). The decision follows the expiration of the applicable option conditions on August 31, 2026, after Scinai and PinCell did not reach an agreement to extend the arrangements.
Scinai Ends PC111 Arrangements to Preserve Capital
Scinai said the conclusion of the PC111 arrangements was not driven by a new negative scientific finding regarding the investigational program. The company continues to recognize the therapeutic potential of PC111, an early-stage program being developed for pemphigus vulgaris, but determined that advancing a preclinical asset would require significant additional capital and time without sufficient visibility on non-dilutive funding. The portfolio decision is therefore primarily a capital-allocation and strategic prioritization measure. Scinai plans to redirect resources toward programs where it believes there are stronger opportunities for development, partnering and commercial value. The company said this approach should reduce prospective near-term R&D commitments while allowing management to focus on its existing technology platform and revenue-generating CDMO operations. The shift also comes as Scinai continues a multi-year research collaboration with the Max Planck Society and University Medical Center Göttingen, which supports development of its NanoAb platform.
NanoAb Platform Targets Multiple Immunology Programs
Scinai’s NanoAb platform uses VHH antibody fragments to develop mono-specific, bispecific and multi-specific therapeutic formats targeting inflammatory and immune-mediated diseases. The company believes the platform can support several therapeutic programs from a common technology base, potentially creating opportunities for pharmaceutical partnerships, co-development and licensing. Scinai is currently advancing two complementary IL-17 programs. One is an intradermal IL-17 program targeting psoriasis, for which the company has an application under evaluation through Poland’s FENG program for approximately €12 million in potential grant financing. The proposed funding is intended to support development from the preclinical stage toward first-in-human readiness, although the timing and outcome of the grant decision remain uncertain. A second systemic IL-17 bispecific program is also being developed as a validation program for the broader NanoAb platform. Scinai identifies in-vivo proof-of-concept as the next major development milestone for this program. The company is also developing a broader portfolio of mono-, bi- and multi-specific NanoAb candidates.
Advertisement
CDMO Business Adds Commercial Growth Opportunity
Scinai’s R&D refocusing is occurring alongside expansion of Scinai Biopharma Services, which provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. As of August 16, 2026, the company reported approximately $3.1 million in committed customer orders across its two facilities and said it continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing and applicable revenue-recognition requirements. Scinai has also begun substantive activities on an expanded clinical manufacturing and chemistry, manufacturing and controls (CMC) program for a U.S.-based biopharmaceutical customer. The program is intended to support a planned U.S. regulatory submission and subsequent Phase III clinical development, with potential expansion into commercial manufacturing. However, the broader scope remains subject to a definitive agreement and the customer’s development and regulatory progress. The company is also evaluating additional potential projects of comparable scope, although these discussions are not committed orders. Scinai believes larger customer programs, repeat business and higher facility utilization could support progress toward sustainable CDMO profitability. The strategic shift therefore positions Scinai around two core priorities: advancing its NanoAb immunology pipeline while expanding its CDMO and cGMP manufacturing business. For cGxP.wire readers, the announcement highlights how emerging biopharmaceutical companies are increasingly balancing proprietary therapeutic development with commercial manufacturing capabilities to improve capital efficiency and create diversified growth opportunities.
Source: Scinai Immunotherapeutics press release
